In November 2016, Novelion was launched through a merger transaction in which Aegerion Pharmaceuticals became an indirect, wholly-owned subsidiary of QLT Inc. In conjunction with the closing of the merger, QLT changed its name to Novelion Therapeutics Inc.
Novelion Therapeutics’ common stock is traded on the NASDAQ Global Select Market and the Toronto Stock Exchange under the ticker symbol "NVLN.”
Novelion does not offer a direct stock purchase plan. Shares of the Company should be purchased through a broker.
Novelion does not currently pay dividends.
To replace lost certificates, contact the transfer agent: www.rtco.com, a free web tool for shareholders.
To change address, contact the transfer agent: www.rtco.com, a free web tool for shareholders.